Clinical trial summaries

This phase III trial investigates the efficacy and safety of guselkumab in patients with psoriatic arthritis.

Sunday, November 10, 11:00–12:30

The RITAZAREM trial aims to compare the efficacy of rituximab versus azathioprine for the maintenance of remission in patients with antineutrophil cytoplasmic antibody-associated vasculitis.

Sunday 10 November, 11:00–12:30

C-VIEW is an open-label phase IV trial investigating the impact of certolizumab pegol treatment on anterior uveitis flares in patients with axial spondyloarthritis.

Sunday, November 11, 16:30–18:00

The ADEM trial aims to establish whether methotrexate reduces pain and structural progression in patients with symptomatic erosive hand osteoarthritis.

Monday, November 11, 11:00–12:30

A study of the efficacy and safety of short-term oral prednisolone in people with painful hand osteoarthritis.

Monday, November 11, 11:00–12:30

TULIP-1 is a phase III trial of add-on anifrolumab versus placebo for the treatment of moderate-to-severe systemic lupus erythematosus.

Monday, November 11, 11:00–12:30

SPIRIT-P3 was designed to compare continued treatment with ixekizumab compared with switching to placebo among patients with psoriatic arthritis achieving minimal disease activity during treatment with the interleukin-17A inhibitor.

Monday, November 11, 14:30–16:00

COAST-X is a placebo-controlled phase III trial of ixekizumab for the treatment of nonradiographic axial spondyloarthritis.

Tuesday, November 12, 11:00–12:30

This study investigates the JAK inhibitor upadacitinib as a treatment option for active ankylosing spondylitis.

Tuesday, November 12, 11:00–12:30